Identification of predictive factors for early relapse in patients with unresectable stage III non-small cell lung cancer receiving consolidation durvalumab after concurrent chemoradiation therapy.
Jung Hyun NamChang Dong YeoChan Kwon ParkSung Kyoung KimJu Sang KimYong Hyun KimJin Woo KimSeung Joon KimSang Haak LeeHye Seon KangPublished in: Thoracic cancer (2023)
Younger age, higher number of pack-years, non-COPD, and anemia were independent predictive factors for early relapse during durvalumab consolidation therapy in patients with unresectable stage III NSCLC after definitive CCRT. Careful patient selection and clinical attention are needed for high-risk individuals.